Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)

ACTRIS was established in April 2020 to meet the increasing clinical demand for cellular therapeutics to treat various life-threatening diseases.
Our vision is to be the national and regional centre of excellence for facilitating discovery, process development, and manufacturing of cellular-based therapeutics across the broad spectrum of immunotherapy and regenerative medicine, encompassing both investigational and clinical-use products for Singapore.
Through its specialised infrastructure and skilled workforce, ACTRIS aims to promote and support the entire value chain of the cell therapy ecosystem by enabling translational research and development, manufacturing, clinical service provision, and commercialisation across the healthcare, academic and industrial sectors.
In addition, ACTRIS will also provide value-added services such as workforce training, regulatory support, and the standardisation of ancillary materials and product testing pertaining to the delivery of cellular therapy to patients.

ACTRIS is a programme of CRIS.